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Abstract
The formation of the essential functional unit of the ovary, the primordial follicle, occurs during fetal life in humans. Factors regulating
oogonial proliferation and interaction with somatic cells before primordial follicle formation are largely unknown. We have investigated the
expression, localisation and functional effects of activin and its receptors in the human fetal ovary at 14–21 weeks gestation. Expression of
mRNA for the activin hA and hB subunits and the activin receptors ActRIIA and ActRIIB was demonstrated by RT-PCR. Expression of hA
mRNA increased 2-fold across the gestational range examined. Activin subunits and receptors were localised by immunohistochemistry. The
hA subunit was expressed by oogonia, and the hB subunit and activin receptors were expressed by both oogonia and somatic cells. hA
expression was increased in larger oogonia at later gestations, but was low in oocytes within newly formed primordial follicles. Treatment of
ovary fragments with activin A in vitro increased both the number of oogonia present and oogonial proliferation, as detected by
bromodeoxyuridine (BrdU) incorporation. These data indicate that activin may be involved in the autocrine and paracrine regulation of germ
cell proliferation in the human ovary during the crucial period of development leading up to primordial follicle formation.
Crown Copyright D 2003 Published by Elsevier Inc. All rights reserved.
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Introduction
Germ cell survival is key to the reproductive life span of
the ovary and is determined by the continuing presence of
oocytes within primordial follicles. These are formed during
fetal life in the human. The number of follicles formed is
dependent upon the balance between early germ cell prolif-
eration and loss, as well as the interaction between oocyte
and somatic cells (Hirshfield, 1991; McLaren, 1991). The
pathways regulating this crucial process are largely un-
known, although several genes necessary for the formation
of a normal complement of primordial follicles have been
identified (Amleh and Dean, 2002; Matzuk, 2000). During
the period leading up to primordial follicle formation there is
massive oogonial mitotic proliferation, both during and after
migration from the yolk sac to the nephrogonadoblastic
ridge. The oogonia associate with somatic cells resulting in
syncitial nests of germ cells intermingled with pre-granulosa
cells and surrounded by a meshwork of ovarian stroma
(Byskov, 1986; Pepling and Spradling, 2001; Sawyer et
al., 2002). The germ cells subsequently enter meiosis only
to arrest at diplotene of the first meiotic division. By mid-
gestation, the human fetal ovary contains its maximal num-
ber of germ cells. This peak is followed by widespread germ
cell loss, by apoptosis, (De Pol et al., 1997; Vaskivuo et al.,
2001) so that less than 20% survive by the time of birth
(Baker, 1963). Primordial follicles are formed as oocytes
become individually surrounded by somatic cells (Hirsh-
field, 1991) and it is this interaction that has been identified
as the event that determines oocyte survival, and presumably
protection against apoptosis. A number of locally derived
growth factors have been identified to be crucial to germ cell
survival at early developmental stages, such as BMP-4
(Fujiwara et al., 2001) and kit ligand (Godin et al., 1991;
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Manova et al., 1990), and following primordial follicle
formation, such as growth and differentiation factor 9
(GDF-9) (Dong et al., 1996). However, little information is
available regarding factors regulating oogonial proliferation
and primordial follicle formation, particularly in human.
Activins and inhibins are members of the transforming
growth factor h (TGFh) family. The component a and h
subunits can be combined into biologically active ah inhibin
or hh activin dimers with generally opposing functional
effects, and are produced in both gonad and pituitary (Burger
and Igarashi, 1988; Chen, 1993; Mather et al., 1997).
Follistatin is a structurally unrelated monomeric protein that
irreversibly binds activin and neutralises its biological effects
(Nakamura et al., 1990; Schneyer et al., 1994). Members of
the TGF superfamily can influence many facets of cell
lineage and activity including proliferation, differentiation,
adhesion, motility and apoptosis. Many are involved in
embryonic development as well as adult tissue homeostasis
(Mishina et al., 1999; Padgett and Patterson, 2001). The
activins, together with other members of the TGFh super-
family, signal through membrane-bound serine-threonine
kinase receptors. They bind to a type II receptor (ActRIIA
or ActRIIB), which recruits and phosphorylates a type I
receptor with subsequent modulation of gene expression via
Smad protein activation (Massague´, 1998). Several type I
receptors, termed activin receptor-like kinases (ALKs) have
been identified. ALK4 (ActRIB) is believed to be the
preferential activin receptor, whereas ALK2 (ActRIA) pref-
erentially mediates BMP and anti-Mu¨llerian hormone sig-
nalling. Whilst the Smad proteins are the central elements in
the activin receptor signalling pathway, other signalling
pathways may mediate at least some of the diverse biological
responses of the TGFh superfamily, including mitogen-
activated protein kinase (MAPK) pathways (Massague,
2000; Mulder, 2000). The initial steps coupling the activin
type II serine-threonine kinase receptor to MAPK are yet to
be defined, although signalling via TGFh-activated kinase 1
(TAK1) results in activation of stress-activated p38 and
transcription factor ATF2, which can interact with Smad3
and Smad4 to mediate transcription (Cocolakis et al., 2001;
Derynck et al., 2001).
A substantial body of evidence has accrued that activins
and inhibins are regulatory factors in the adult ovary in-
volved in a wide range of functions, including folliculo-
genesis, granulosa and theca cell proliferation, and
steroidogenesis (Findlay et al., 2002; Knight and Glister,
2001; Mizunuma et al., 1999) as well as oocyte maturation
(Alak et al., 1998; Izadyar et al., 1998). Activin is expressed
in the human gonad at very early stages of development
(Harkness and Baird, 1997) and there are limited data
indicating the expression of activin and inhibin in the
developing human ovary following primordial follicle for-
mation (Harkness and Baird, 1997; Rabinovici et al., 1991).
However, no data are available regarding the presence of
activin and its cognate receptors before primordial follicle
formation in the human ovary. We have therefore explored
the expression and distribution of inhibin/activin subunits in
the human fetal ovary during the period of oogonial prolif-
eration leading up to primordial follicle formation. The
localisation of activin receptors ALK4, ActRIIA and
ActRIIB, the inhibin receptor betaglycan (Lewis et al.,
2000) and the activin-binding protein follistatin has also
been investigated to identify potential sites of action of these
regulatory factors during this period of development. As
oogonia in the mid-trimester human fetal ovary were found
to express activin subunits and receptors, we have investi-
gated the effect of activin A on oogonial survival and
proliferation using an in vitro tissue culture model.
Materials and methods
Tissues
Human fetal ovaries were obtained following medical
termination of pregnancy. Women gave consent according to
national guidelines (Polkinghorne, 1989) and the study was
approved by the Lothian Paediatrics/Reproductive Medicine
Research Ethics Subcommittee. Termination of pregnancy
was induced by treatment with mifepristone (200 mg orally)
followed 48 h later by prostaglandin E1 analogue (Geme-
prost; Beacon Pharmaceuticals, Tunbridge Wells, UK) 1 mg
three hourly per vaginum. None of the terminations were for
reasons of fetal abnormality, and all fetuses appeared mor-
phologically normal. Gestational age was determined by
ultrasound examination before termination and confirmed
by subsequent direct measurement of foot length.
Ovaries were dissected free and either fixed for immuno-
histochemical analysis, snap frozen and stored at 70jC,
placed in 500 Al RNAlater (Ambion (Europe) Ltd, Hunting-
don, Cambs, UK) or further dissected and placed into
culture. Fixation was carried out in Bouin’s fluid for 5 h,
followed by transfer to 70% ethanol before processing into
paraffin using standard methods.
Isolation of RNA and synthesis and amplification of cDNA
Total RNAwas extracted from fetal ovary (14–19 weeks)
using either the Rneasy Mini Kit (Qiagen, Crawley, UK) for
RT-PCR or TRIReagent (Sigma, Poole, Dorset, UK) for
quantitative PCR analysis according to the manufacturers’
instructions, and treated with DNase (Gibco, Paisley, UK).
Reverse transcription using a first-strand cDNA synthesis kit
(Roche Diagnostics, Lewes, UK) was followed by PCR
using 1 Al cDNA samples and Taq DNA polymerase (AGS
Gold; Hybaid, Ashford, UK) as previously described (Rob-
inson et al., 2001). Primers were designed to span an intron
to ensure that genomic DNA was not amplified. Specific
primers for each subunit and receptor are given in Table 1.
Control tubes were run in parallel for each PCR, one in
which water replaced RNA and a second RT-sample in which
reverse transcriptase was omitted, to ensure there was no
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genomic DNA contamination. The identity of all PCR
products were confirmed by direct sequencing using an
Applied Biosystems 373A automated sequencer.
Lightcycler quantitative PCR
Quantitative PCR was performed using the Lightcycler
system (Roche Molecular Biochemicals, Sussex, UK) as
previously described (Hartley et al., 2002) to investigate
changes in expression of the activin hA subunit over a range
of gestations. Reverse transcribed RNA samples (n = 29)
were diluted in water as indicated. One microliter of diluted
first-strand cDNA was added to a final volume of 10
Al containing 2 mM MgCl2 and 0.5 AM each of forward
and reverse primer in 1 Lightcycler Fast Start DNA
MasterSYBR Green 1 Master Mix (Roche Molecular Bio-
chemicals). Signal acquisition was performed for each of 45
amplification cycles followed by continuous melt curve
analysis to ensure product accuracy. Primers for GAPD
and activin hA subunit are given in Table 1.
Standard curves for GAPD and activin hA were derived
by making a series of first-strand cDNA dilutions from a 16-
week ovary. The number of cycles needed to yield a
fluorescent signal above background (the cross-over point,
Cp) was plotted against the log of relative concentration
using LightCycler Software (Molecular Dynamics Ltd.,
Buckinghamshire, UK) yielding a straight line for each
product. Quantification of ovarian hA mRNA expression
was subsequently performed. For each experiment, both
GAPD and activin hA amplification reactions were per-
formed in duplicate for every cDNA sample used. Calcu-
lations for activin hA mRNA concentration were made
relative to GAPD from the same sample to allow compar-
isons between ovaries. Allowance for differences in ampli-
fication rate for GAPD and activin hA was achieved by
determining the actual amount of amplification required to
yield a signal for each target. Data were analysed by
ANOVA.
Immunohistochemistry
Sections (5 Am) were mounted on BDH Superfrost Plus
slides (BDH Laboratory Supplies, Merck Ltd, Lutterworth,
Leics, UK) and dried overnight at 50jC before processing
for immunohistochemistry as previously described (Ander-
son et al., 2002). Briefly, slides were incubated in 3%
H2O2 in methanol for 30 min to inhibit endogenous
peroxidase activity. After rinsing in distilled water, slides
were washed twice in Tris-buffered saline (TBS; 0.05 mol/
l Tris, 0.85% NaCl, pH 7.6) for 5 min and blocked for 30
min in appropriate serum (Diagnostics Scotland, Carluke,
UK) diluted 1:5 in TBS containing 5% bovine serum
albumin. Sections were then blocked with avidin and
biotin (both from Vector, Peterborough, UK) with washes
in TBS in between. Various primary antibodies were used.
Rabbit antibodies to Activin receptor II (ActRIIA) and
Activin receptor IIB (ActRIIB) were kindly donated by Dr.
C-H Heldin, Ludwig Institute for Cancer Research,
Uppsala, Sweden, and used at a concentration of 1:600
and 1:400, respectively. Rabbit antibodies to ALK2 and
ALK4 were also kindly donated by Dr, C-H Heldin,
Ludwig Institute for Cancer Research, Uppsala, Sweden,
and both used at concentration 1:150. Goat antibody to
betaglycan (Santa Cruz Biotechnology, CA, USA) was
used at a dilution of 1:25. Mouse monoclonal primary
antibodies to the inhibin/activin subunits included a sub-
unit (173.9k) used at a range of dilutions 1:1000 to 1:100,
hA subunit (E4) at 1:1000 and hB subunit (12/13) at
1:100, all the gift of NP Groome. Monoclonal antibody
directed against recombinant follistatin FS288, which rec-
ognises follistatin even when bound to activin, was used at
a range of dilutions 1:200 to 1:25, also gift of NP Groome
(Majdic et al., 1997). All were incubated at 4jC overnight.
Sections were then washed and incubated for 30 min with
goat anti-rabbit (Santa Cruz Biotechnology), rabbit anti-
goat (Dako, Cambridge, UK) or rabbit anti-mouse (Diag-
nostics Scotland) biotinylated secondary antibody as ap-
propriate, at a dilution of 1:500. Following washes in TBS,
sections were incubated with avidin-biotin-horseradish per-
oxidase linked complex (Dako) according to the manufac-
turer’s instructions. Bound antibody was visualised using
3,3V-diaminobenzidine tetrahydrochloride (Dako). Nonim-
mune serum was used in place of primary antibody for
negative controls. Positive controls (human fetal testis for
activin/inhibin subunits and receptors and adult rat testis
for follistatin) were also run in parallel.
Sections were counterstained with haematoxylin, dehy-
drated, mounted and visualised by light microscopy.
Images were captured using an Olympus Provis micro-
scope (Olympus Optical Co., London) equipped with
Kodak DCS330 camera (Eastman Kodak Co, Rochester,
NY).
Table 1
Sequences of PCR primers
Primers 5V 3V
ActRIIA GCAAAATGAATACGAAGTCTA GCACCCTCTAATACCTCTGGA
ActRIIB CAACTTCTGCAACGAGCGCTT GCGCCCCCGAGCCTTGATCTC
Inhibin a TGAGGGCCCTGTTCTTGGATG CTGGCGGCTGCGTGTATGCTG
Inhibin/activin hA GAACTTATGGAGCAGACCTCGG TTGCCATCACACTCCAAGCC
Inhibin/activin hB GCCAGGAGCGCGTTTCCGAAATC CCGCTCGCCCCGCTCAAACAAG
GAPD GACATCAAGAAGGTGGTGAAGC GTCCACACCCTGTTGCTGTAG
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Nuclear diameter measurement
The size distribution of germ cells expressing activin hA
subunit was determined in specimens of 18–19 weeks
gestation. To avoid bias, sequential nonoverlapping frames
were captured using the Provis image analysis system, and
the diameter of all germ cell nuclei within the frame
measured. Strongly immunostained germ cells were classi-
fied as hA positive, all other germ cells as negative. Data
were analysed by the Mann–Whitney U test as the distri-
bution deviated from normal. For graphical representation,
numbers of immunopositive and immunonegative cells were
grouped in 1-Am increments of nuclear diameter. The
nuclear diameter of a total of 527 germ cells was measured.
Primary cell culture
Fetal ovaries were dissected and cultured in MEMa
medium with phenol red (GibcoBRL, Life Technologies)
supplemented with 2 mM pyruvate, 2 mM glutamine, 1
ITS supplement (Sigma) and 3 mg/ml BSA, and with
penicillin, streptomycin and amphotericin. A total of seven
ovaries were used for culture experiments. Fetal ovaries
(14–17 weeks) were dissected in prewarmed and gassed
medium to yield tissue fragments approximately 1 mm3.
Between four and six fragments were transferred in 400-
Al medium to each of four designated wells containing
inserts (Millicell-CM; Millipore UK Ltd, Watford, UK) in
a 24-well tissue culture plate such that tissue fragments
were supported at the meniscus of the medium. Tissue was
cultured for 17 h in a humidified incubator at 37jC and
5% CO2. Two treatment groups were cultured with 100 ng/
ml recombinant human activin A (R&D systems, Abing-
don, UK). The other two groups acted as controls. Bro-
modeoxyuridine (BrdU; Sigma) was supplemented at 10
Al/ml as a marker of cell proliferation. In each experiment,
BrdU was present in the media of one control and one
treatment group for the duration of the experiment. BrdU
was added to the other control and treatment group for the
final 4 h of tissue culture only. Analysis of germ cell
number in these parallel cultures allowed confirmation that
changing the medium 4 h before the end of the culture
period did not influence the results. At the end of culture,
tissues were washed in PBS and fixed in Bouin’s fluid for
1 h, followed by processing to visualise BrdU incorpora-
tion by immunohistochemistry.
Serial sections (5 Am), four sections per slide, were
mounted on BDH Superfrost Plus slides (BDH Laboratory
Supplies) and dried overnight at 50jC. Every fourth slide
was processed for immunohistochemistry as described
above. The primary antibody used was formalin-grade
anti-BrdU mouse monoclonal antibody (Roche) at a dilution
of 1:30, incubated at 4jC overnight. On completion of the
immunohistochemistry protocol, sections were counter-
stained with haematoxylin, dehydrated and mounted before
analysis.
Sections of uncultured control and cultured tissue were
analysed to quantify the effects of culture and activin A on
the number and proliferation of germ cells. Analysis was
carried out blind using the Area Fraction Probe in the
Stereologer software programme (Systems Planning and
Analysis Inc, Alexandria, VA, USA) as previously described
(Robinson et al., 2003; Sharpe et al., 2002). Tissue was
serially sectioned and sections greater than 20 Am apart
were counted, ensuring the same cells were not counted
more than once. The counting was performed using a 121
point grid in the eyepiece of the microscope. Each tissue
fragment was outlined and frames randomly selected there-
after by the programme. The number of points lying outside
the tissue in any grid was also recorded and the total cell
numbers were corrected for this. Average number of germ
cells per grid was calculated for each experimental condi-
tion, and data were analysed using paired t tests.
Results
Expression of mRNAs for activin/inhibin subunits and
receptors
mRNA expression was detected by RT-PCR using RNA
extracted from human fetal ovaries (Fig. 1). Amplicons of
expected sizes corresponding to the inhibin a (278 bp),
inhibin/activin hA (274 bp) and hB (325 bp) subunits and
the activin receptors ActRIIA (435 bp) and ActRIIB (283
bp) were amplified from cDNA derived from ovaries across
14–19 weeks gestation. Product identity was confirmed by
direct sequencing.
Quantitative PCR
Changes in the expression of the activin hA subunit
mRNA between 14 and 19 weeks gestation were investi-
gated by quantitative RT-PCR. There was an approximately
2-fold increase in the relative expression of the hA subunit
mRNA expression between 14 and 19 weeks gestation (P <
0.001, Fig. 2). The increase in expression was not contin-
uous across the gestational range examined, but mostly
occurred between 17 and 19 weeks.
Immunohistochemistry
Inhibin/Activin subunits
Expression of the hA inhibin/activin subunit protein was
detected in the fetal ovary at all gestations investigated. It
was specifically localised to the germ cell cytoplasm at all
gestations studied, but a marked change in the pattern of
immunostaining was seen across the gestational range (Figs.
3D–F). At 14 weeks gestation, a gradient of distribution
was observed. Oogonial immunostaining was detected
throughout the ovary, but was most marked at the periphery,
particularly in germ cells in the outermost few layers of the
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gonad. At 17–19 weeks gestation, a different distribution of
immunostaining had emerged with a discrete subpopulation
of germ cells showing intense staining. These germ cells
tended to be larger oocytes, and were distributed in small
clusters of less than 10 largely located in the medullary
region of the ovary. However, oocytes within newly formed
primordial follicles showed only weak or no immunostain-
ing for activin hA.
Differential expression of hA subunit by larger germ
cells was confirmed by direct measurement of nuclear
diameter. A total of 527 germ cells were measured, of
which 79 (15%) were intensely immunopositive for the
hA subunit. These hA-expressing germ cells were signifi-
cantly larger than those only weakly immunopositive or
immunonegative (11.3 F 0.2 vs. 9.8 F 0.1 Am, P = 0.0001,
Fig. 4) although the very largest germ cells with nuclear
diameter >16 Am, that is, those within primordial follicles,
were immunonegative.
Expression of hB inhibin/activin subunit protein was
also detected throughout the ovary across the range of
gestations examined. Immunostaining was widespread, with
both germ cells and stromal cells expressing the hB subunit
(Figs. 3G–I). However, at the periphery of the ovary, some
germ and somatic cells did not express the hB subunit.
There was no difference in distribution of immunostaining
of either stromal or germ cells between 14 and 18 weeks
gestation. Two antibodies directed against the hB subunit
(C12/13 monoclonal antibody, gift of NP Groome, and a-
cyclic inhibin hB (80-112)-NH2 PBL#197 rabbit polyclon-
al, gift of W Vale) were used, with similar results.
Immunostaining for the inhibin a subunit was not
detected in any cell type in the human fetal ovary across
a range of gestations and despite using a wide range of
antibody titres. Fetal testes were used as a positive control
and showed immunostaining in both Leydig cells in the
interstitium and Sertoli cells in the seminiferous tubules as
previously described (Figs. 3A–C) (Anderson et al.,
2002).
Activin and inhibin receptors
Expression of the type II receptor ActRIIA was detected
at all gestations from 14 to 21 weeks and was localised
specifically to germ cell cytoplasm (Figs. 5C, D). There was
no immunostaining in stromal cells or the pre-granulosa
Fig. 2. Real-time PCR quantification of hA expression in the fetal ovary.
Expression of hA subunit mRNA was quantified in human fetal ovary
specimens over the gestational range 14–19 weeks. Data calculated as hA
mRNA expression relative to GAPD for ovaries of 14, 15, 16, 17, 18 and 19
weeks gestation (n = 6, 5, 5, 5, 3 and 5, respectively, mean F SEM). SEM
for 15 weeks = 0.00. *P < 0.001 by ANOVA.
Fig. 1. Expression of mRNA for inhibin/activin subunits and type II activin
receptors in the human fetal ovary. RT-PCR analysis of samples extracted
from human fetal ovaries at 14, 16 and 19 weeks gestation. mRNA
expression for inhibin/activin subunits and receptors ActRIIA and ActRIIB
as indicated. Lanes marked 14, 16 and 19 contained samples in which
reverse transcriptase was omitted. W refers to water instead of cDNA in the
PCR reaction. The size of each amplicon is indicated on the right.
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cells of primordial follicles, nor cells at the ovarian surface.
There was no significant difference in distribution across the
gestational range studied.
ActRIIB immunoexpression was distributed widely with-
in the fetal ovary at all gestations from 14 to 21 weeks (Figs.
5E, F). Immunostaining was detected in both stromal and
germ cells but not in the cells at the ovarian surface. Intense
immunostaining was noted in larger germ cells at later
gestations and expression persisted in cytoplasm of oocytes
organising into primordial follicles.
Expression of ALK4 protein, the preferential activin
type I receptor, was detected throughout the ovary
predominantly in stromal and pre-granulosa cells but also
with weak expression in germ cells (Fig. 5A). At 14
weeks gestation, ALK4 immunostaining clearly demarcat-
ed a meshwork of ovarian stromal cells with weaker
immunostaining of the oogonia intermingled with more
strongly immunopositive pre-granulosa cells. At later
gestations (18 weeks), the ovarian stroma was less
strongly immunopositive, and the predominant site of
ALK4 expression was the pre-granulosa cells surrounding
individual and grouped oogonia, although oogonia
remained weakly immunopositive.
In contrast to ALK4, expression of ALK2 protein was
exclusively localised to the stromal cells at 14–18 weeks
gestation, with no immunostaining identified in germ cells at
any gestation (Fig. 5B). Intense immunostaining was partic-
ularly notable in many pre-granulosa cells between and
Fig. 4. Size distribution of hA-immunopositive germ cells in the human
fetal ovary. Histogram shows the frequency of distribution of nuclear
diameter of cells strongly immunopositive for hA subunit (filled columns)
and those either weakly immunopositive or immunonegative for hA subunit
(open columns) in human fetal ovary at 18–19 weeks gestation. n = 79 and
n = 448, respectively.
Fig. 3. Immunohistochemical localisation of inhibin/activin subunits in human fetal ovary. (A) Inhibin a subunit, 14-week ovary. (B) Inhibin a subunit, 19-
week ovary. (C) Inhibin a subunit positive control, 19-week testis. (D) hA subunit, 14-week ovary. (E) hA subunit, 17-week ovary (inset shows negative
control). (F) hA subunit, 17-week ovary at higher magnification. (G) hB subunit, 14-week ovary. (H) hB subunit, 18-week ovary (inset shows negative
control). (I) hB subunit, 18-week ovary at higher magnification. Positive staining in all panels is brown and sections are counterstained with haematoxylin. o,
oogonia; s, stroma; t, tubule; i, interstitium. Scale bars in A–H, 50 Am, F and I, 20 Am.
S.J. Martins da Silva et al. / Developmental Biology 266 (2004) 334–345 339
outlining germ cells. This pattern of stromal cells immunos-
taining appeared to increase with increasing gestation and the
formation of primordial follicles.
No expression of h-glycan protein was detected in any
mid-trimester gestation ovary studied. Intense immunos-
taining was detected in the peritubular cells of fetal testes
used as a positive control (Figs. 5G, H).
In all cases, negative controls showed no immunostain-
ing. Fetal testis sections were used as a positive control,
and showed distinct immunostaining as previously de-
scribed (Anderson et al., 2002).
Follistatin
No expression of follistatin was detected in any mid-
trimester ovary studied (14–20 weeks gestation). Adult rat
testis was used as a positive control and showed positive
immunostaining in Leydig cells as previously described
(Majdic et al., 1997).
Fig. 5. Immunohistochemical localisation of inhibin/activin receptors in human fetal ovary. (A) ALK2, 14-week ovary. (B) ALK4, 18-week ovary. (C)
ActRIIA, 14-week ovary. (D) ActRIIA, 21-week ovary (inset shows negative control). (E) ActRIIB, 14-week ovary. (F) ActRIIB, 21-week ovary (inset shows
negative control). (G) Betaglycan, 14-week ovary. (H) Betaglycan-positive control, 15-week testis. Positive staining in all panels is brown and sections are
counterstained with haematoxylin. s, stroma; g, pre-granulosa cells; o, oogonia; pf, primordial follicle; t, tubule; p, peritubular cells. Scale bars, 50 Am in all
panels.
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Tissue Culture
A total of seven separate experiments were carried out to
investigate the effect of activin on germ cell survival and
proliferation in vitro, using ovaries between 14 and 17
weeks gestation. Comparison of germ cell number in control
cultures showed good oogonial survival (46 F 2 oocytes per
grid after 17 h culture vs. 68 F 2 in uncultured tissue) and
there was no effect of changing the medium 4 h before the
end of culture period in those experiments where BrdU was
added at that time point (45 F 4 germ cells per grid in
controls vs. 46 F 3 in those in which the medium was
changed). Treatment with 100 ng/ml activin A resulted in a
significant increase in total number of germ cells. Activin
A-treated groups showed a mean increase of 20% in the
total number of germ cells from 45 F 4 to 56 F 4 per grid,
P = 0.001. Very similar results were obtained in the cultures
in which BrdU was present for 4 h (Fig. 6A). When BrdU
was present in the culture medium for the duration of culture
(17 h), more germ cells were immunopositive than when
BrdU was present for only the final 4 h of culture, as
expected (6.4 F 1 vs. 2.8 F 0.4 stained germ cells per grid
when exposed to BrdU for only 4 h). Activin A treatment
also resulted in a significant increase in number of BrdU-
immunopositive germ cells. There was a 44% increase in
number of immunostained germ cells (9.2 F 1.3 vs. 6.4 F
0.8 per grid, P = 0.01) when cultured with activin A and
BrdU for 17 h. Immunostained germ cells were increased by
89% (5.3 F 0.9 vs. 2.8 F 0.4 per grid, P < 0.05) when
cultured with activin A for 17 h and exposed to BrdU for
only the final 4 h of culture (Figs. 6B, C).
Discussion
High interspecies conservation of activins, inhibins and
activin receptors and the universal presence of activins in
mammals, birds, amphibians and fish suggest an evolution-
Fig. 6. Analysis of the effect of activin A on the number of germ cells in human fetal ovary. (A) Graph shows the number of germ cells per grid for time 0 tissue
(shaded column), control groups (open columns) and groups cultured for 17 h with 100 ng/ml recombinant activin A (filled columns) in human fetal ovary at
14–17 weeks gestation (meanF SEM). Treatment and control groups were either exposed to BrdU for 4 h or for the duration of culture (17 h) as indicated. *P
< 0.05; **P = 0.001 vs. control. (B) Graph shows the number of BrdU-immunopositive germ cells per grid for control groups (open columns) and those
cultured for 17 h with 100 ng/ml recombinant activin A (filled columns) in human fetal ovary at 14–17 weeks gestation (meanF SEM). Treatment and control
groups were either exposed to BrdU for 4 h or for the duration of culture (17 h). *P < 0.05; **P = 0.01 vs. control. Example of immunohistochemical staining
of BrdU in cultured human fetal ovary. (C) Control 17-week ovary cultured for 17 h with BrdU. (D) Seventeen-week ovary cultured with 100 ng/ml
recombinant activin A and BrdU for 17 h. Positive staining in all panels is brown and sections are counterstained with haematoxylin. o, oogonia; b, BrdU-
immunopositive oogonia. Scale bar, 50 Am.
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arily conserved role of these proteins in animal develop-
ment. Activins have potent effects on early amphibian
embryonic events during mesoderm-forming (Nieuwkoop)
induction both in vitro and in vivo (Dyson and Gurdon,
1997). In mammals, activins have also been demonstrated to
have morphogenetic effects, notably in renal tubule devel-
opment (Ritvos et al., 1995). However, there are few
published data available concerning the presence, expres-
sion and potential roles of activins, inhibins and their
receptors during mammalian gonadal development. Whilst
activin is thought to act primarily in an autocrine and/or
paracrine manner, inhibin acts primarily as an endocrine
feedback regulator of pituitary FSH release (Welt et al.,
2002). Our data demonstrate the presence and localisation of
activin receptors and subunits within the developing human
ovary, and suggest a role for activin A in the regulation of
germ cell proliferation during the developmental period
leading up to primordial follicle formation. In contrast,
follistatin was not expressed. Follistatin binds and neutral-
ises activin activity. It also binds several other TGFh
superfamily members, including BMP4 (Fainsod et al.,
1997; Lin et al., 2003). Follistatin expression has been
detected in the fetal sheep ovary at late gestation, but not
before primordial follicle formation (Braw-Tal et al., 1994).
Similarly, follistatin is not expressed in the developing
human or rat testis (Majdic et al., 1997) despite the presence
of activin subunits and receptors (Anderson et al., 2002). It
would therefore appear that activin activity in the develop-
ing human gonad is not regulated by follistatin.
Transgenic mice have been generated to study physio-
logical models deficient in inhibins, activins and their
receptors (Burns and Matzuk, 2002). Gene knockout experi-
ments have been inconclusive in determining activin func-
tion in vivo, but functional analysis would suggest that
activins are not essential for mammalian mesoderm forma-
tion. A number of reasons are cited to explain the lack of
definitive conclusions from this body of work; firstly, some
mutations are lethal, secondly, deficient activin ligand or
receptor signalling results in a phenotype with suppressed
FSH which results in reproductive and developmental
defects and thirdly, there may be some functional overlap
between TGFh superfamily ligand and receptor signalling.
Mutations in the gene encoding the hA subunit are lethal.
Mutant mice develop to term but have secondary palate
defects and lack whiskers and lower incisors (Matzuk et al.,
1995b). The mutant mice die within 24 h of birth due to
feeding difficulties and there are thus no conclusions re-
garding ovarian follicular development. Mice lacking the
hB subunit suffer eye lesions as a result of failed eyelid
fusion. Mutant females do not show a disruption in follic-
ular development but manifest impaired reproduction char-
acterised by perinatal lethality of their offspring (Vassalli et
al., 1994). Highly increased hA expression was noted in the
ovaries of these hB-deficient female mice, suggesting the
possibility of functional compensation within the TGFh
superfamily. Using a gene knockin approach, it has been
found that activin hB can rescue the craniofacial defects and
neonatal lethal phenotype of hA-deficient mice. However,
activin hB is unable to substitute for all the functions of hA.
The hB knockin mouse is subfertile and phenotypic abnor-
malities in the gonads and external genitalia, as well as
delayed lethality remain in these mice. Ovaries in the
hemizygous knockin female mouse are much smaller than
those of controls (Brown et al., 2000). This may suggest
activin hA expression is necessary for development of the
correct complement of germ cells in the mouse ovary,
consistent with the present data in the human. It is interest-
ing that mice carrying a null mutation in the ActRII gene do
not, as one might expect, phenocopy activin-deficient mice.
Despite lacking a crucial component of the activin signal-
ling pathway, only 25% of these mice die at or shortly after
birth with mandible defects. Surviving adults have defective
reproductive performance and small gonads although this
may be in part due to abnormal FSH secretion in addition to
deficient germ cell proliferation (Matzuk et al., 1995a).
There is also some evidence that it is the second messenger
(Smad) signalling which is more crucial to specific embry-
onic and extra-embryonic development pathways than par-
ticular ligand and receptor interactions (Chang et al., 2001).
Activin subunits and receptors showed a differential
distribution within the developing ovary. Activins bind to
a type II receptor (ActRIIA or ActRIIB), which recruits and
phosphorylates a type I receptor with subsequent modula-
tion of gene expression via Smad protein activation (Mas-
sague´, 1998) Several type I receptors (ALKs) have been
identified. ALK4 (ActRIB) is believed to be the preferential
activin receptor. The activin hA subunit was specifically
expressed by germ cells, whereas both somatic and germ
cells expressed the hB subunit. ActRIIA was specifically
localised to germ cells, whereas ActRIIB and the type I
receptor ALK4 were expressed by both stromal and germ
cells. The distinct distribution of both activin subunits and
receptor subtypes between germ cells and somatic cells
suggest that activin may have several distinct roles in
ovarian development and organisation, and more specifical-
ly in germ cell regulation. This is supported by observations
of an increase in hA mRNA expression as well as changes
in the pattern of hA protein expression across the mid-
trimester. With increasing gestation, intense hA expression
was found in small clusters of larger, more mature germ
cells. However, the largest oocytes, within primordial fol-
licles, show little or no hA expression. This pattern suggests
that the increase in hA subunit expression may be transient
as the germ cells mature, with reduction of gene expression
following primordial follicle formation. Increased expres-
sion however may be associated with differences in subse-
quent survival, consistent with the effects of activin on
oogonial survival as demonstrated in the tissue culture
experiments here described.
Despite detecting inhibin a subunit mRNA by RT-PCR,
we were unable to demonstrate the protein by immunohis-
tochemistry. Previous studies suggest that activin but not
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inhibin is present in the human fetal ovary at mid-gestation
(16–23 weeks) (Rabinovici et al., 1991). Rabinovici et al.
localised the hA subunit to primordial follicles by immu-
nohistochemistry, but did not observe immunostaining for
hB or a subunits. In contrast, immunostaining for all three
subunits was detected in late gestation fetal rhesus monkey
ovary, which contained primordial and early growing fol-
licles. Furthermore, culture medium from mid-gestation
human fetal ovaries was found to contain undetectable
levels of inhibin-a by radioimmunoassay. Recent immuno-
localisation studies performed in baboons revealed minimal
to nondetectable levels of a subunit in mid- and late-
gestation ovaries (Billiar et al., 2003) and there is also
indirect evidence from in situ hybridisation studies on
primate ovaries that follicles preferentially synthesise acti-
vin rather than inhibin in the early stages of development
(Schwall et al., 1990; Yamoto et al., 1993). The putative
inhibin receptor betaglycan (Lewis et al., 2000) was also not
detected in the mid-trimester human fetal ovary. The fact
that neither the a subunit nor betaglycan receptor were
identified by immunohistochemistry in mid-trimester human
fetal ovaries indicates that inhibin is not a regulatory factor
at this stage of development, but becomes of importance
later during follicular growth (Welt et al., 2002).
An in vitro tissue culture model was used to investigate
the effect of activin on oogonial survival and proliferation.
Activin A treatment resulted in an increase in germ cell
proliferation and survival in fetal ovary tissue fragments.
This concurs with the earlier demonstration that activin A
stimulated [3H] thymidine incorporation in vitro in the
differentiating rat ovary (Kaipia et al., 1994). BrdU was
used as a marker for cell proliferation. It is interesting to
note that immunostaining was observed predominantly
towards the edge of cultured ovarian fragments. This may
represent a diffusion effect, but may also partly reflect the
organisation of the tissue. Mitotically dividing germ cells
tend to be placed peripherally in the mid-trimester fetal
ovary with a gradient of maturity across the developing
ovary such that relatively more mature cells are found in the
medulla compared to the cortex (Byskov, 1986). A recent
study of follicle formation during fetal development in
sheep also noted a cortical pattern of distribution of BrdU
staining following in vivo administration (Sawyer et al.,
2002), which became more pronounced up to primordial
follicle formation.
In the adult ovary, activin A induces expression of genes
signalling cellular differentiation and maturation. In the
developing fetal ovary, key events involve germ cell prolif-
eration, organisation and survival by somatic cell interaction
and primordial follicle formation (Hirshfield, 1991; McLa-
ren, 1991). The present data support a role of activin A in
germ cell survival and proliferation. The Bcl-2 family of
proteins are key regulators of apoptosis in many cell types.
This family comprises pro-apoptotic (Bax, Bad and Bak)
and anti-apoptotic (Bcl-2, Bcl-XL and Mcl-1) subfamilies.
Mcl-1 is a rapidly inducible short-term effector of cell
viability and is expressed in a subset of oocytes at the time
of primordial follicle formation (Hartley et al., 2002). The
distribution of Mcl-1 in the fetal ovary is similar to that of
activin hA subunit and it is possible that activin A promotes
cell survival by signalling via Mcl-1, as has been demon-
strated in a leukaemia cell line (Fukuchi et al., 2001). Whilst
both activin A and Mcl-1 expression are most marked in
larger oogonia preceding primordial follicle expression,
oocytes within primordial follicles continue to express
Mcl-1, whereas activin hA expression is low once that
developmental stage is reached. It is possible that activin
and Mcl-1 constitute part of the signalling pathway that
determines survival for a small proportion of the oogonia in
the mid-trimester ovary.
In conclusion, we have found the human fetal ovary to
be a site of expression of activin subunits and receptors
before the formation of primordial follicles. Protein ex-
pression of the inhibin a subunit and the betaglycan
receptor was not detected. The distribution of activin
subunits and receptors suggests that whilst somatic cells
may produce any of the activin forms, oogonia only
produce activin A, and is consistent with an autocrine
and/or paracrine mode of action for activins within the
developing ovary. Increased expression of hA by larger/
more mature oogonia may reflect selection for follicle
formation and data from tissue culture experiments support
activin A as a regulatory factor in fetal germ cell prolif-
eration and survival. These data suggest that activin may
be of particular importance during the period of develop-
ment immediately preceding primordial follicle formation.
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